News|Articles|November 17, 2026

AR1001 Slows Decline in Monotherapy Group of Phase 3 Alzheimer Trial

Fact checked by: Isabella Ciccone, MPH
Listen
0:00 / 0:00

Key Takeaways

  • POLARIS-AD randomized 1535 early AD patients to AR1001 30 mg vs placebo for 52 weeks, with multiplicity allowing success if either prespecified population met CDR-SB significance.
  • In the monotherapy cohort (n=604), CDR-SB favored AR1001 by –0.44 points (P=.0266), described as 31% slowing; overall effect was –0.11 (P=.4015).
SHOW MORE

In the global, randomized, double-blind, placebo-controlled phase 3 POLARIS-AD (NCT05531526) trial, AR1001 (AriBio) slowed clinical decline by 31% on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) in the prespecified monotherapy population of individuals with early Alzheimer disease (AD), according to topline results announced by the company.1 The investigational, once-daily oral phosphodiesterase 5 (PDE5) inhibitor did not achieve statistical significance on the same end point in the overall trial population.

The data were presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held November 16 to 19, 2026, in Boston, Massachusetts. Sharon J. Sha, MD, MS, chief of the Memory Disorders Division at Stanford University and global principal investigator of POLARIS-AD, presented the 52-week findings. The monotherapy population, one of 2 prespecified primary analysis populations, consisted of participants who were not receiving an acetylcholinesterase inhibitor or memantine at baseline.1

"The CDR-SB finding in the prespecified Monotherapy population and the safety profile are encouraging," Sha said in a statement.1 "The secondary endpoints and biomarker findings warrant further evaluation alongside the Overall population outcome to understand AR1001's therapeutic effects in early Alzheimer's disease."

The findings provide additional data on an investigational oral, non-antibody approach to early AD treatment. AR1001 is a blood-brain barrier-penetrant PDE5 inhibitor designed to enhance cyclic guanosine monophosphate (cGMP) signaling. Preclinical research has suggested that the agent may influence several disease-related pathways, including cerebral perfusion, neuroprotection, neuroinflammation, and tau phosphorylation.1

AR1001 efficacy on CDR-SB in the phase 3 POLARIS-AD trial

POLARIS-AD enrolled 1535 participants with early AD at approximately 230 sites in 13 countries.1 Participants received AR1001 30 mg or placebo once daily for 52 weeks, and the primary end point was change from baseline to week 52 on CDR-SB.1 The primary efficacy objective required a statistically significant treatment difference in at least 1 of the 2 prespecified populations under a multiplicity procedure.1

In the monotherapy population (n = 604), AR1001 produced a CDR-SB treatment difference of –0.44 points vs placebo at week 52 (P = .0266), which the company characterized as a 31% slowing of clinical decline.1 In the overall population (n = 1535), the treatment difference was –0.11 points (P = .4015), numerically favoring AR1001 without reaching statistical significance.

In total, 1349 participants (87.9%) completed the 52-week double-blind period.1 Of these, 1284 (95.2%) entered the optional 52-week open-label extension, in which all participants receive AR1001 30 mg daily, with completion expected in the third quarter of 2027.1

Frequently Asked Questions

What is AR1001?

AR1001 is an investigational once-daily oral PDE5 inhibitor from AriBio designed to cross the blood-brain barrier and enhance cGMP signaling. It is not approved by the FDA or any other regulator for Alzheimer disease.

What did the POLARIS-AD trial show?

AR1001 met its primary efficacy objective in the prespecified monotherapy population, with a –0.44-point CDR-SB difference vs placebo at week 52 (P = .0266). The overall population difference of –0.11 points (P = .4015) was not statistically significant.

What are the next steps for AR1001?

AriBio plans to discuss the complete findings with the FDA and present additional analyses at future conferences. The open-label extension is expected to conclude in the third quarter of 2027.

AR1001 secondary end points, biomarkers, and safety profile

Secondary cognitive and functional measures numerically favored AR1001 in both populations, with larger effects in the monotherapy group.1 In the monotherapy population, the Alzheimer's Disease Assessment Scale–Cognitive Subscale 13 treatment difference was –1.16 points vs placebo (P = .0798), and the Mini-Mental State Examination difference was 0.7 points (P = .0232), a finding the company described as nominally significant.1

AR1001 increased cerebrospinal fluid (CSF) cGMP vs placebo at week 52 in both the overall (P < .0001) and monotherapy (P = .0058) populations, which the company said supports target engagement in the central nervous system.1 CSF phosphorylated tau 217 differences were –3.52 pg/mL overall (P = .1784) and –5.34 pg/mL in the monotherapy group (P = .0402), and investigators observed no difference in the CSF amyloid-β 42/40 ratio at 52 weeks.1

Treatment-emergent adverse events occurred in 69.0% of AR1001-treated participants and 66.4% of placebo recipients, with serious adverse events in 10.0% and 9.8%, respectively.1 Fatal adverse events occurred in 4 participants (0.5%) receiving AR1001 and 2 (0.3%) receiving placebo.1 The most common nonserious adverse events with AR1001 were diarrhea (7.7% vs 4.4%), falls (7.3% vs 5.9%), and dizziness (6.1% vs 3.1%), and adverse events led to discontinuation of study drug in 5.2% vs 1.7% of participants.1

AriBio plans to discuss the complete findings with the FDA to inform next steps and to present additional analyses at future scientific conferences.1 The company is also developing AR1005, an oral candidate in phase 2 development for dementia with Lewy bodies.1

Additional Context

AR1001's development in AD was informed by findings from an earlier phase 2 trial (NCT03625622), which evaluated the agent in 210 participants with mild to moderate AD. Although the study did not meet its primary end point in the overall population, a subgroup analysis presented at the 2025 Alzheimer's Association International Conference (AAIC), held July 27-31, in Toronto, Canada, identified a potential monotherapy signal.2

Among participants not receiving concomitant AD medications, AR1001 30 mg daily was associated with a statistically significant 4.019-point improvement from baseline on the Alzheimer's Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog13) at week 26 (P = .012). Reductions in plasma phosphorylated tau 181 and 217 were also observed in this subgroup.2

REFERENCES
1. AriBio Co., Ltd. AriBio's oral AR1001 meets primary efficacy objective in prespecified monotherapy population in phase 3 POLARIS-AD trial. News release. GlobeNewswire. November 16, 2026. Accessed November 17, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404242/0/en/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-population-in-phase-3-polaris-ad-trial.html
2. Kim F, Xi T, Lee HJ, Rock JA, Kim S, Choung JJ. Evaluating AR1001 as monotherapy from a phase 2 study in mild to moderate Alzheimer’s disease patients. Presented at: Alzheimer’s Association International Conference (AAIC) 2025; July 27–31, 2025; Toronto, Canada. Abstract 107781.

Related to this article